144954 20260217205541.0 doi 10.3390/biomedicines12081763 sideral 139737 ART-2024-139737 eng Atrián-Blasco, Elena (orcid)0000-0002-3830-7847 Heteronuclear Complexes with Promising Anticancer Activity against Colon Cancer 2024 Access copy available to the general public Unrestricted This study investigates the activity of novel gold(I) and copper(I)/zinc(II) heteronuclear complexes against colon cancer. The synthesised heteronuclear Au(I)-Cu(I) and Au(I)-Zn(II) complexes were characterised and evaluated for their anticancer activity using human colon cancer cell lines (Caco-2). The complexes exhibited potent cytotoxicity, with IC50 values in the low micromolar range, and effectively induced apoptosis in cancer cells. In the case of complex [Cu{Au(Spy)(PTA)}2]PF6 (2), its cytotoxicity is ×10 higher than its mononuclear precursor, while showing low cytotoxicity towards differentiated healthy cells. Mechanistic studies revealed that complex 2 inhibits the activity of thioredoxin reductase, a key enzyme involved in redox regulation, leading to an increase in reactive oxygen species (ROS) levels and oxidative stress, in addition to an alteration in DNA’s tertiary structure. Furthermore, the complexes demonstrated a strong binding affinity to bovine serum albumin (BSA), suggesting the potential for effective drug delivery and bioavailability. Collectively, these findings highlight the potential of the investigated heteronuclear Au(I)-Cu(I) and Au(I)-Zn(II) complexes as promising anticancer agents, particularly against colon cancer, through their ability to disrupt redox homeostasis and induce oxidative stress-mediated cell death. info:eu-repo/grantAgreement/ES/CIBERObn/CB06-03-1012 info:eu-repo/grantAgreement/ES/DGA/B16-23R info:eu-repo/grantAgreement/ES/DGA/E07-23R info:eu-repo/grantAgreement/ES/MICINN AEI/PID2019-104915RB-I00 info:eu-repo/grantAgreement/ES/MICINN AEI/PID2022-13686INB-I00 info:eu-repo/grantAgreement/EUR/SUDOE/INTERREG/NEWPOWER-S1-1.1-E01116 info:eu-repo/semantics/openAccess by https://creativecommons.org/licenses/by/4.0/deed.es 3.9 2024 PHARMACOLOGY & PHARMACY 88 / 352 = 0.25 2024 Q1 T1 BIOCHEMISTRY & MOLECULAR BIOLOGY 114 / 320 = 0.356 2024 Q2 T2 MEDICINE, RESEARCH & EXPERIMENTAL 65 / 195 = 0.333 2024 Q2 T2 1.114 2024 Medicine (miscellaneous) 2024 Q1 Biochemistry, Genetics and Molecular Biology (miscellaneous) 2024 Q1 6.8 2024 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Sáez, Javier Rodriguez-Yoldi, Maria Jesús Universidad de Zaragoza (orcid)0000-0002-3595-7668 Cerrada, Elena Universidad de Zaragoza (orcid)0000-0003-2457-3674 2010 760 Universidad de Zaragoza Dpto. Química Inorgánica Área Química Inorgánica 1012 410 Universidad de Zaragoza Dpto. Farmac.Fisiol.y Med.L.F. Área Fisiología 12, 8 (2024), 1763 [20 pp.] Biomedicines 2227-9059 4258122 http://zaguan.unizar.es/record/144954/files/texto_completo.pdf Versión publicada 2768209 http://zaguan.unizar.es/record/144954/files/texto_completo.jpg?subformat=icon icon Versión publicada oai:zaguan.unizar.es:144954 articulos driver 2026-02-17-20:36:17 ARTICLE